The adamantane family of drugs has an unusual origin story: their core chemical scaffold looks like a tiny carbon “cage,” and that geometry makes the molecules unusually lipid-friendly—good at slipping through membranes, including the blood–brain barrier.

Clinically, two adamantanes dominate the neuroscience conversation: amantadine (older; antiviral and antiparkinsonian uses) and memantine (approved for moderate–severe Alzheimer’s disease).

A newer wave of papers has revived an old idea—that the same chemistry that helps these drugs reach the brain might also make them candidates for “nootropic” use.

But when you read the clinical literature, a more nuanced picture emerges: adamantanes are better described as context-dependent neuromodulators than as general intelligence boosters.

Damping Runaway Excitation

Both amantadine and memantine interact with the brain’s glutamate system, particularly NMDA receptors, which sit at the heart of synaptic plasticity—learning-related changes in how neurons connect.

NMDA receptors are essential for normal memory formation, but they are also a common pathway for excitotoxicity (damage from excessive calcium influx during prolonged glutamatergic overactivation).

Memantine is often described as a low-to-moderate affinity, uncompetitive NMDA antagonist: it preferentially reduces pathological, sustained activation while sparing the fast signaling patterns needed for everyday cognition. That “signal-preserving brake” is the rationale behind its use in neurodegenerative and brain-injury contexts.

This mechanism also hints at why nootropic claims are tricky. The same receptor family that supports memory formation can, if blocked too strongly (or in the wrong brain state), impair learning or produce neuropsychiatric side effects—a broader pattern seen across NMDA antagonists.

Memantine

The strongest cognitive evidence for an adamantane comes from memantine in moderate–severe Alzheimer’s disease. In a large 28-week randomized trial (Reisberg et al. 2003), memantine produced less deterioration than placebo on functional and cognitive measures.

For example, on the Severe Impairment Battery (SIB), the mean change (end point, last observation carried forward) was −4.0 ± 11.34 with memantine versus −10.1 ± 13.50 with placebo (P < 0.001). On daily functioning (ADCS-ADLsev), decline was −3.1 ± 6.79 with memantine versus −5.2 ± 6.33 with placebo (P = 0.02).

Those numbers illustrate the clinical “shape” of memantine’s benefit: it doesn’t restore normal cognition, but it can meaningfully slow the slide in later-stage dementia.

Combination therapy

When memantine is added to donepezil in moderate-to-severe disease, pooled analyses of randomized trials suggest a consistent advantage. In a post-hoc meta-analysis of two 24-week RCTs (Atri et al. 2013), memantine+donepezil outperformed placebo+donepezil with standardized mean differences of 0.36 (cognition), 0.21 (function), and 0.23 (global status) in the moderate–severe subgroup (all last observation carried forward).

Importantly, marked clinical worsening (decline across cognitive, functional, and global domains simultaneously) occurred in 8.7% of memantine+donepezil patients versus 20.4% of placebo+donepezil patients (P = 0.0002). This is not the profile of a stimulant-like enhancer. It’s closer to a disease-course buffer.

In mild Alzheimer’s disease, the evidence is notably less supportive. A meta-analysis of trials (Schneider et al. 2011) found no significant differences between memantine and placebo across several outcomes; the pooled mean difference on ADAS-cog was −0.17 (95% CI −1.60 to 1.26), essentially indistinguishable from noise in clinical terms.

Brain radiation: a clearer “cognitive-protection” signal

One of the most quantitatively persuasive cognitive findings for memantine comes from oncology, where the brain is pushed into an injury-like state.

In a randomized trial during whole-brain radiotherapy (Brown et al. 2013), memantine significantly delayed time to cognitive decline (hazard ratio 0.78, 95% CI 0.62–0.99, P = .01). The probability of cognitive failure at 24 weeks was 53.8% with memantine versus 64.9% with placebo.

Usage Outside of Cognitive Decline

A rare window into memantine’s “nootropic-like” reputation comes from a sleep-deprivation challenge model in healthy adults (Kwong et al. 2020). After 24 hours awake, placebo participants showed a −3.0% change in N-back accuracy, while the memantine condition showed a smaller decline (−1.4%, P = 0.027).

Reaction time on a rapid visual processing task increased by +41.3 ms under placebo versus +16.1 ms with memantine (P = 0.034). That pattern matters: memantine looked less like a cognitive “turbo” and more like a stability aid under strain, and even then the effects were modest.

Epilepsy

Small or non-definitive studies continue to explore memantine in diverse cognitive contexts (psychiatric illness, epilepsy-related impairment, aging complaints).

For instance, in epilepsy patients with cognitive complaints (Marimuthu et al. 2016; 16-week randomized trial), memantine was associated with improvements on cognitive/memory measures and self-ratings; the paper reports strong statistical signals (e.g., MMSE and memory scale changes reaching P < 0.001), alongside side effects such as dizziness (11.5% memantine vs 3.4% placebo) in that small cohort.

But heterogeneity is the rule: in adolescents and young adults with Down syndrome, a randomized phase 2 trial concluded that cognition-enhancing effects were not recorded at 20 mg/day (Costa et al. 2022).

Safety

Memantine is often well tolerated in trials, but its adverse effects are very “brain-drug flavored”: dizziness, confusion, and hallucinations appear in labeling and reviews, and controlled datasets show that some CNS events are not rare.

In the combination dataset summarized by Atri et al. (2013), for example, confusional state occurred in 5.6% with memantine+donepezil versus 2.4% with placebo+donepezil (in the moderate–severe subgroup), while dizziness was about 7–9% in both arms.

Amantadine

Amantadine is pharmacologically “messier” than memantine: it has NMDA-related effects but also interacts with dopamine signaling (including dopamine release and reuptake modulation), which helps explain why it has been used in Parkinson’s disease and in disorders of arousal and motivation after brain injury.

The best-known modern result is in prolonged disorders of consciousness after severe TBI. In a placebo-controlled trial (Giacino et al. 2012), recovery during the 4-week treatment period was significantly faster with amantadine, quantified as a difference in slope of 0.24 points per week on the Disability Rating Scale (P = 0.007).

Cognitive Enhancement following TBI

This is a striking clinical effect, but its meaning is often misunderstood in popular “nootropics” framing: the outcome is functional recovery from an impaired consciousness state, not enhancement above baseline human performance.

A 2025 updated meta-analysis of randomized trials in TBI (Félix et al. 2025) found that compared with placebo, amantadine was associated with:

• Higher Glasgow Coma Scale at day 7: mean difference +1.50 (95% CI 0.08–2.92, P = 0.038)
• Higher MMSE: mean difference +3.23 (95% CI 0.53–5.94, P = 0.019)

But pooled effects were not significant for DRS overall (MD −0.50, 95% CI −4.17 to 3.17, P = 0.789; heterogeneity I² = 86%) or for Glasgow Outcome Scale (MD −0.13, P = 0.320).

In other words, depending on which outcome you ask and when you measure it, amantadine can look like a cognitive improver—or like a wash.

A separate 2024 systematic review with trial sequential analysis (Siy et al. 2024) underscores that fragility. In their primary random-effects model, functional improvement did not reach significance (SMD −0.24, 95% CI −1.50 to 1.01, P = 0.71; heterogeneity I² = 92%).

Yet a fixed-effect model suggested benefit (SMD −0.61, 95% CI −0.88 to −0.34, P < 0.0001), illustrating how conclusions can pivot on assumptions about between-study differences.

Mixed Results

If amantadine were a true general cognitive enhancer, we’d expect benefits in people living with chronic impairment. A large multi-site randomized controlled trial in chronic TBI (Hammond et al. 2018) found the opposite pattern early on: at day 28, placebo improved more than amantadine on composite cognitive indices. The placebo group showed greater improvement in:

• General Cognitive Index: +6.2 percentile points (95% CI 2.3–10.1, P = 0.002)
• Learning/Memory Index: +10.2 points (95% CI 4.0–16.3, P = 0.001)

By day 60, between-group differences were no longer significant.

That’s an unusually direct warning for self-experimenters: even if a drug can accelerate recovery in one injured brain state, it may blunt cognitive performance (or expected practice effects) in another.

Side effects: arousal is a double-edged sword

Amantadine’s adverse effects often map onto overstimulation and neuropsychiatric vulnerability: insomnia, agitation, and hallucinations are recurring concerns in clinical reviews, particularly in older patients or those with renal impairment (amantadine is renally cleared). The TBI and dementia-adjacent literature repeatedly emphasizes careful monitoring rather than casual use.

Adamantanes as a nootropic

Where memantine and amantadine look best is when cognition is threatened—by neurodegeneration, radiation injury, sleep deprivation, or severe brain trauma—and even then, effects are typically modest, domain-specific, and not always consistent across trials or scales.

A more defensible takeaway from current research is this:

• Memantine is best supported as a cognitive decline modulator in moderate–severe Alzheimer’s and as a cognitive-protection adjunct in settings like whole-brain radiotherapy, with measurable (but not miraculous) effect sizes.
• Amantadine is best supported as a recovery-accelerator in certain severe TBI states, with mixed evidence on standard cognitive tests and at least one strong trial suggesting early cognitive downsides in chronic TBI.

And because both drugs act on neural systems that are central to plasticity and perception, the boundary between “stabilizing” and “disrupting” cognition can be narrow, especially outside medically supervised indications.

References

Danysz, W., Hansen, N., Wiltfang, J., & Kornhuber, J. (2025). Memantine: updates from the past decade and implications for future novel therapeutic applications. Journal of Neural Transmission. https://link.springer.com/article/10.1007/s00702-025-03017-8

Danysz, W., Dekundy, A., Schick, B., et al. (2021). Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials. Journal of Neural Transmission. https://pmc.ncbi.nlm.nih.gov/articles/PMC7901515/

Egunlusi, A. O., & Joubert, J. (2024). NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders. Pharmaceuticals. https://www.mdpi.com/1424-8247/17/5/639

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J.; Memantine Study Group. (2003). Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa013128

Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013). Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimer’s Research & Therapy. https://alzres.biomedcentral.com/articles/10.1186/alzrt160

Schneider, L. S., Dagerman, K. S., Higgins, J. P. T., & McShane, R. (2011). Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Archives of Neurology / JAMA Neurology (online). https://jamanetwork.com/journals/jamaneurology/fullarticle/1107815

Brown, P. D., Pugh, S., Laack, N. N., et al. (2013). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial (RTOG 0614). Neuro-Oncology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3779047/

Kwong, A. C., Cassé-Perrot, C., Perrot, X., et al. (2020). An Alzheimer Disease Challenge Model: 24-Hour Sleep Deprivation in Healthy Volunteers, Impact on Working Memory, and Reversal Effect of Pharmacological Intervention: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Journal of Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/32332458/

Marimuthu, P., Varadarajan, S., Krishnan, M., et al. (2016). Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: A double-blind placebo-controlled clinical trial (Phase IIIb pilot study). Annals of Indian Academy of Neurology. https://pubmed.ncbi.nlm.nih.gov/27570386/

Costa, A. C. S., et al. (2022). Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology. https://pubmed.ncbi.nlm.nih.gov/34942135/

Giacino, J. T., Whyte, J., Bagiella, E., et al. (2012). Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1102609

Félix, J., et al. (2025). Use of amantadine in traumatic brain injury: an updated meta-analysis of randomized controlled trials. Frontiers in Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11790432/

Siy, H. F. C., et al. (2024). Amantadine in traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. (Journal on ScienceDirect). https://www.sciencedirect.com/science/article/pii/S2772529424000298

Hammond, F. M., et al. (2018). Amantadine Did Not Positively Impact Cognition in Chronic Traumatic Brain Injury: A Multi-Site Randomized Controlled Trial. Journal of Neurotrauma. https://pmc.ncbi.nlm.nih.gov/articles/PMC6157374/